Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02756637 · ClinicalTrials.gov registry record
Neutrophil-to-Lymphocyte Ratio in Bladder Cancer: A Secondary Biomarker Analysis of SWOG 8710
A clinical trial, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- 634
- Enrollment target
NCT02756637: Completed study, sponsored by Abramson Cancer Center at Penn Medicine.
NCT02756637 is a clinical trial that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 634 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02756637 has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- 634 participants
- Enrollment target
Study Summary
The purpose of this study is to perform a secondary analysis of SWOG 8710 to assess NLRs value as a biomarker. Specifically, the investigators test two hypotheses: 1) that baseline NLR is correlated with overall survival after curative treatment for BC and 2) that baseline NLR is correlated with the survival benefit of NAC. The study will look at the data from participants of the SWOG 8710 study.
Primary Outcome
Number of participants who survived at 26 years are reported.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 634 participants |
| Start Date | 2016-04 |
| Est. Completion | 2016-11 |
What the finished NCT02756637 record still lists
NCT02756637 is an observational study that tracks outcomes without assigning an intervention. The registered 634 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02756637 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02756637 about?
NCT02756637 is a clinical study titled "Neutrophil-to-Lymphocyte Ratio in Bladder Cancer: A Secondary Biomarker Analysis of SWOG 8710". The purpose of this study is to perform a secondary analysis of SWOG 8710 to assess NLRs value as a biomarker. Specifically, the investigators test two hypotheses: 1) that baseline NLR is correlated with overall survival after curative treatment for BC and 2) that baseline NLR is correlated with the...
What is the current status of trial NCT02756637?
This trial is currently completed. The enrollment target is 634 participants. The study started on 2016-04. Estimated completion is 2016-11.
Who is sponsoring clinical trial NCT02756637?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573027 · 634 participants · NA
Heart Disease of the Small Arteries in Women and Men
- NCT04108156 · 634 participants · Phase 3
A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME
- NCT07237295 · 634 participants · NA
CommunityRx-Kidney Health
- NCT03478826 · 635 participants
Creation of a Biospecimen Repository From Patients With Interstitial Lung Diseases (ILD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia